



GLOBAL VACCINE SAFETY INITIATIVE

2018
MEETING REPORT



World Health
Organization

WHO/MVP/EMP/SAV/2019.01

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Global Vaccine Safety Initiative. Report of a meeting, Santiago, Chile, 8-9 October 2018. Geneva: World Health Organization; 2019 (WHO/MVP/EMP/SAV/2019.1). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout by Paprika, Annecy, France

Photos ©Adobe stock

GLOBAL VACCINE SAFETY INITIATIVE

2018
MEETING REPORT



World Health
Organization

CONTENTS

Introduction	7
OPENING	9
Key note address: Moving towards an integrated system for sustainable development.	12
SESSION 1	15
THE GLOBAL VACCINE SAFETY INITIATIVE	15
The Global Vaccine Safety Initiative: A review of achievements	16
The Global Vaccine Safety Observatory	17
SESSION 2	19
VACCINE PHARMACOVIGILANCE IN THE AMERICAS	19
Vaccine pharmacovigilance in Latin America: Progress, challenges and collaboration	20
Experience and lessons learnt from Mexico's strengthening of its vaccine safety surveillance system	21
Vaccine pharmacovigilance in the USA: a strong collaboration between the FDA and the CDC	22
SESSION 3	25
COLLECTION AND PROCESSING OF VACCINE SAFETY DATA: GLOBAL REGIONAL AND COUNTRY EXPERIENCES	25
An introduction to the WHO's minimum data elements and its practical applications	26
National experience in applying the minimum data elements for vaccine safety – An experience from Chile	27
Regional experiences in applying the minimum data elements for vaccine safety – The African experience	28
IVI experience in supporting countries in implementing a Vaccine Adverse Events Information Monitoring System	29
SESSION 4	31
MONITORING THE SAFETY OF ROTAVIRUS VACCINES	31
From the first rotavirus vaccine introductions to the present day: Rotavirus vaccine availability, use and impact	32
Intussusception surveillance and results from Africa	33
Surveillance systems for intussusception in India	34
Should we continue to actively monitor the safety of rotavirus vaccines?	35

SESSION 5

RISK ASSESSMENT AND RISK MANAGEMENT: THE CASE OF DENGUE VACCINE

- Updated safety profile of the first licensed dengue vaccine (Dengvaxia®)
- Global mechanisms for risk assessment and risk management: WHO advisory bodies (GACVS and SAGE)
- Brazil's experience in dealing with emerging safety data

39

SESSION 6

VACCINE SAFETY COMMUNICATION IN TODAY'S WORLD

- Lessons learnt from HPV vaccine introduction in Republic of Ireland
- The rabies and DTaP vaccine incident in People's Republic of China
- Using social media for safety communication during a Japanese encephalitis vaccine campaign in Myanmar

39

40

41

42

45

45

46

47

48

SESSION 7

EDUCATING CHILDREN, PARENTS AND HEALTH CARE PROFESSIONALS ON VACCINE SAFETY

- Introducing vaccines and immunization in schools – a game-based educational module by WHO EURO
- US CDC experiences in education and vaccine safety
- Vaccine safety education for health care professionals – Chile's experience

51

51

52

53

54

SESSION 8

SAFETY OF VACCINATION IN PREGNANT WOMEN AND THEIR NEONATES

- Vaccination in pregnant women in Latin America and the Caribbean
- Vaccines recommended for pregnant women: Current status and future prospects
- Building bridges and harmonizing approaches in maternal interventions vigilance

57

57

58

59

60

SESSION 9

ENGAGING VACCINE MANUFACTURERS IN SAFETY SURVEILLANCE AND PHARMACOVIGILANCE

- Perspectives from the International Federation of Pharmaceutical Manufacturers (IFPMA) on vaccine post-marketing safety surveillance
- Perspectives from the Developing Countries Vaccine Manufacturers Network (DCVMN) on challenges and opportunities of strengthening pharmacovigilance in emerging countries
- Experience from PATH: impact and benefits of collaboration between industry, regulators and technical agencies on strengthening national pharmacovigilance systems

63

63

64

65

67

APPENDICES

- Appendix 1: acronyms
- Appendix 2: list of participants

71

72

74



Introduction

The seventh meeting of the Global Vaccine Safety Initiative (GVS^I) was held in Santiago, Chile, on 8–9 October 2018. It was hosted by the Institute of Public Health of Chile, together with the Ministry of Health of Chile.

The meeting provided a platform for exchange, interaction and information sharing between Member States and partners, as well as opportunities for partnership-building and planning.

The meeting enabled Member States and partners to discuss progress in the implementation of national and global vaccine pharmacovigilance activities.

Participants had opportunities to share ideas, explore new frontiers in vaccine safety, and initiate collaborations.

Attendees included immunization program managers, pharmacovigilance staff from national regulatory authorities, representatives of UN agencies, academic institutions, umbrella organizations of pharmaceutical companies, technical partners, industry representatives and funding agencies.

This report provides an overview of presentations and key points discussed during the meeting.

Meeting objectives:

- To review progress in implementing the GVS^I.
- To address new challenges and opportunities in vaccine safety.
- To facilitate further partnerships and inter-sectoral collaborations.
- To identify means to promote regulatory harmonization initiatives for vaccine pharmacovigilance.
- To examine progress with the Global Vaccine Safety Observatory.



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25382

